Impel NeuroPharma Appoints Meghan Swardstrom as Vice President of Clinical Operations

New Vice President will build clinical operations department while leading several early stage clinical programs

December 12, 2017 — On December 6^th, Impel NeuroPharma, Inc. announced the appointment of seasoned clinical operations leader, Meghan Swardstrom, as Vice President of Clinical Operations.

“Impel has made tremendous progress in just twelve months with one clinical program already completing its first phase, two others preparing to start, and a fourth currently run by NIH collaborators,” said Dr. Stephen Shrewsbury, Impel’s Chief Medical Officer. “We are delighted that Meghan has joined us as we rapidly build an experienced clinical group to oversee these programs in 2018 and beyond.”

Jon Congleton, Impel’s CEO, adds, “We are growing rapidly, particularly in clinical operations, and look forward to a successful execution of an ambitious clinical program next year and beyond.”

Meghan Swardstrom has over 20 years’ experience in clinical operations including working at University of Washington, Gilead, Seattle Children’s Research Institute, Nohla Therapeutics, and most recently as Principal for Emerald Clinical Consulting.

“I am excited to be joining Impel’s busy and growing clinical department where we are using the unique Precision Olfactory Delivery™, or POD™, for numerous clinical programs,” noted Meghan Swardstrom. “Impel has some great opportunities, just in the near future, to bring important medicines to the market, which are testament to the dedicated and hard-working team built by John Hoekman, PhD. Impel’s Founder, Executive Vice President, and Chief Scientific Officer.”